BlossomHill Therapeutics, Inc. (NASDAQ:BLSM – Get Free Report) General Counsel Vincent Paul Liptak bought 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $15.80 per share, for a total transaction of $39,500.00. Following the completion of the acquisition, the general counsel directly owned 109,212 shares in the company, valued at approximately $1,725,549.60. This represents a 2.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Vincent Paul Liptak also recently made the following trade(s):
- On Monday, August 10th, Vincent Paul Liptak purchased 2,200 shares of BlossomHill Therapeutics stock. The stock was acquired at an average price of $16.00 per share, for a total transaction of $35,200.00.
BlossomHill Therapeutics Stock Performance
BlossomHill Therapeutics stock traded down $0.01 during mid-day trading on Monday, hitting $15.99. The company’s stock had a trading volume of 417,968 shares. BlossomHill Therapeutics, Inc. has a twelve month low of $15.25 and a twelve month high of $17.25.
See Also
- Five stocks we like better than BlossomHill Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
